Biotech

Truqap plus Faslodex approved in Japan for HR +ve breast cancer

Truqap plus Faslodex approved in Japan for HR +ve breast cancer

Biotech /

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy. The approval […]

Truqap plus Faslodex approved in Japan for HR +ve breast cancer Read More »

AstraZeneca To Acquire Fusion For Cancer Treatment

AstraZeneca To Acquire Fusion For Cancer Treatment

Biotech /

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates for cancer treatment AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients

AstraZeneca To Acquire Fusion For Cancer Treatment Read More »

New Biomarker Data Supports SPINRAZA in Infants/Toddlers

New Biomarker Data Supports SPINRAZA in Infants/Toddlers

Biotech /

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy Biogen Inc. has announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA

New Biomarker Data Supports SPINRAZA in Infants/Toddlers Read More »